Dabrafenib US FDA Label
- Compound: N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
- Description: Dabrafenib is an organofluorine compound and antineoplastic agent, used as its mesylate salt in treatment of metastatic melanoma. It has a role as an antineoplastic agent, a B-Raf inhibitor and an anticoronaviral agent. It is a sulfonamide, an organofluorine compound, a member of 1,3-thiazoles and an aminopyrimidine.
- Brand Name:
- Code(s): GSK2118436
- Approved:
- Kinase Class: S/T
- Inhibitor Type: I ½A
- Literature (PubMed): 0
- Target(s): B-Raf proto-oncogene, serine/threonine kinase
- Disease(s): anaplastic thyroid cancer , melanoma , non-small-cell lung carcinoma